News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Investors Behind Sprout Accuse Valeant (VRX) of Bungling Marketing of Female Libido Drug



11/3/2016 5:53:52 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
The investors behind Sprout Pharmaceuticals, the drugmaker that developed what came to be known as "female Viagra" are suing Valeant Pharmaceuticals.

They claim that Valeant failed to commercialize the drug, pushed Sprout into a deal with Valeant's secret pharmacy just days before it faced accusations of fraud, and hiked the drug's price to a point that made it too costly.

Valeant acquired Sprout for $1 billion in August 2015. The deal was struck right after Sprout won approval for Addyi, which intends to treat women with chronically low sex drives, a condition called hypoactive sexual desire disorder (HSDD).

Read at Business Insider
Read at Bloomberg
Read at Fortune
Read at Financial Times


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES